Optimo Medical Raises Additional CHF 1.8m to Expand Eye Surgery Planning Portfolio

Optimo Medical has successfully closed a 1.8 million Swiss Franc ($1.95 million) finance round, and now looks to expand its product portfolio in eye surgery planning. 

The funding will help establish recent partnerships with Ansys and MicroSurgical Technology to equip eye surgeons with the latest, simulation-based technology.

Based on accurate eye measurements, the Optimo Medical's first product, Optimeyes, creates a digital copy of the patient’s eye inside the computer. With this so-called digital twin, the software then carries out a virtual eye surgery and, prior to the actual surgery, calculates the optimal parameters for each individual eye. By doing so, a superior clinical outcome is actively supported. Every year, about 30 million cataract surgeries are performed across the globe with the majority requiring a correction of astigmatism: a perfect fit for the concept.

The CE-certified and clinically validated [1] Optimeyes technology is based on patient-specific biomechanical simulations and has the potential to serve the needs in ophthalmic procedures, beyond cataract surgery. Several areas have been identified by the team and collaborating experts and defining the requirements has already begun.

“With the recent closing of the growth financing round, we continue our endeavor to deliver cutting-edge technology to fight astigmatism. Moreover, our digital twin technology has potential far beyond this first application. This has been recognized by our customers, partners, and shareholders, who all support us to extend the Optimeyes technology much further," Dr. Harald Studer, co-founder and CEO of Optimo Medical, said in a company news release. "We are only at the beginning of what the Optimeyes simulation technology can do for surgeons and patients all over the world. With our compelling digital twin technology, and together with our customers, we are capable to deliver on our promises. In order to augment and broaden our product portfolio, business activities and talent recruitment to strengthen the development team in Biel will soon be started.”

The funding is provided by existing and undisclosed new shareholders.